The chronic recurrent aphthous stomatitis (CRAS) is one of the most common diseases of the oral mucosa, characterized by severe inflammatory tissue reaction with formation of erosive and ulcerative elements and relapsing course. The inflammation and tissues alteration are the dominant pathomorphologic processes in inflammatory and destructive oral mucosa diseases that are going with forming erosive and ulcerative elements. After necrotizing of the top layer of epithelium with emerging serous exudate effusion, the surface of erosions begins to be covered with grayish-white coat owing to additional secondary bacterial infection. Therefore, for topical treatment of erosive elements drugs that have antimicrobial and antiinflammatory effect are used.
Using the FarGALS in complex therapy of CRAS in pregnant women reduces the duration of the treatment and the frequency of relapses. Anti-bacterial and antiiinflammatory properties of the FarGALS are directed against the risk of infection and inflammation in the wound. This creates optimal conditions to stimulate the activity of neutrophils and macrophages, which lead to cleansing erosive and ulcerative surfaces and intensive filling of mucosal defect. The lack of irritating effect on the mucous preserves its integrity. Intact mucosa is an important source of the epithelial layer covering erosion: the microenvironment activates a sufficient number of viable cells that activate healing.
The CRAS topical treatment with the FarGALS in pregnant women showed higher clinical effect of healing erosive and ulcerative surfaces compared to chlorhexidine.
The complex CRAS treatment of pregnant women with topical use of the FarGALS and intaking laktobakterin and bifidumbacterin probiotics provides a timely and stable treatment result, which means reduction of general intoxication symptoms and CRAS local manifestations on the oral mucosa. It also allows achieving a stable remission and prevention of subsequent relapses.
The method of application: dilute 1 ml with distilled water in 1: 2; use two-three times a day topically for 5 minutes during one to three days in the form of applications moderately impregnated with the drug.